相关临床试验
96
20 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
1.0%
已完成
31
32.3%
尚未招募
19
19.8%
招募中
17
17.7%
终止
1
1.0%
Unknown
23
24.0%
撤回
4
4.2%
暂无批准数据
- China Medical University (CMU) and Healthcare System secured 17 awards at the Taiwan National Innovation Awards, recognizing breakthroughs in biotechnology and smart healthcare. - Ever Supreme Bio Technology, a CMU spin-off, developed CAR001, an allogeneic CAR-T cell therapy targeting solid tumors with high precision. - Preclinical trials of CAR001 demonstrated a 90% tumor eradication rate, leading to Phase I and IIa clinical trial approvals in Taiwan and the United States. - CMU's innovations extend to AI-driven drug discovery, exosome-based therapies for cancer and neurodegenerative diseases, enhancing treatment outcomes.
- Sacituzumab tirumotecan (sac-TMT) monotherapy shows promising antitumor activity in patients with previously treated advanced endometrial cancer, with an objective response rate (ORR) of 34.1%. - In patients with previously treated advanced ovarian cancer, sac-TMT monotherapy achieved an ORR of 40.0% and a disease control rate (DCR) of 75.0%. - The phase 2 KL264-01 trial highlights a manageable safety profile for sac-TMT, with common treatment-related adverse events including anemia and decreased white blood cell count. - A phase 3 trial, TroFuse-005 (NCT06132958), is underway to further evaluate sac-TMT versus chemotherapy in advanced endometrial cancer patients.
